Superworth

Lumexa Imaging LMRI

Medical - Diagnostics & Research, Healthcare
$11.15
−2.28%
Market cap
$1.1B
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for LMRI, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
$245M$251.4M$252.5M$264.2M
SG&A$17.5M$18.7M$20.3M$24.4M
$25.5M$27.7M$19.4M$23M
Interest expense$29.8M$30.1M$16.3M$16.2M
Pre-tax income−$4.3M−$2.4M$3.1M$5.8M
$3.4M$4.8M$1.4M$3M
Net income−$7.7M−$7.2M$1.7M$2.7M
−$0.11−$0.10$0.02$0.03
69.5M69.5M96M96M

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Diagnostics & Research nearest Lumexa Imaging's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
LMRILumexa Imaging$1.1Bn/mn/an/mn/mn/m
NRCNRC Health$536.6M97.0×35.2×3.8×−0%4.2%
VCYTVeracyte$3.9B35.0×66.2×7.0×+17%20.4%
CDNACareDx$4.5B35.9×19.2×9.1×+39%25.9%
BLLNBillionToOne$5.2B170×152×13.1×+90%9.5%
LNTHLantheus$6.5B24.3×24.0×4.2×+2%17.7%
CAICaris Life Sciences$9.1B86.8×78.4×9.2×+85%10.6%
BIOBio-Rad Laboratories$9.8B44.4×30.9×3.8×+1%8.6%
Peer median$5.2B44.4×35.2×7.0×+17%10.6%

More on Lumexa Imaging

Each number over time

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .